Cidara Market Capitalization from 2010 to 2024

CDTX Stock  USD 20.40  2.95  16.91%   
Cidara Therapeutics Market Cap yearly trend continues to be fairly stable with very little volatility. Market Cap is likely to outpace its year average in 2024.
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Cidara Therapeutics over the last few years. It is Cidara Therapeutics' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 143.75 M10 Years Trend
Slightly volatile
   Market Cap   
       Timeline  

Cidara Market Capitalization Regression Statistics

Arithmetic Mean137,093,849
Geometric Mean113,296,024
Coefficient Of Variation61.94
Mean Deviation79,355,088
Median69,417,371
Standard Deviation84,916,427
Sample Variance7210.8T
Range183.4M
R-Value(0.81)
Mean Square Error2729.7T
R-Squared0.65
Significance0.0003
Slope(15,290,654)
Total Sum of Squares100951.2T

Cidara Market Capitalization History

2024116.9 M
202369.4 M
202252.8 M
201666.6 M

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Cidara Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.